| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| BioDelivery Sciences International, Inc. |
| 185 South Orange Avenue, Newark, NJ 07103 * (973) 972-0015 |
| Business Description | The company is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines, and over-the-counter drugs. |
|
Filing Information Not yet | |||
| To Trade As | BDSI (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 11/7/2001 |
| Domestic Shares Filed | 2,000,000 | Filing Range | $5.25 - $6.00 |
| Foreign Shares Filed | 0 | Offering Amount | $11,250,000 |
| Company Shares | 2,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 10,215,702 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Roan / Meyers Associates, L.P. | Lead Manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/2000 | 6/30/2000 | 6/30/2001 | ||||
| Revenues | - | - | - | - | 0.056 | - | 0.028 |
| Income from Oper. | - | - | - | - | -0.797 | - | -1.422 |
| Net Income | - | - | - | - | -0.673 | - | -1.406 |
| E.P.S | - | - | - | - | -0.040 | - | -0.090 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | - | - | - | ||||
| Cash Flow - Inv. | - | - | - | ||||
| Cash Flow - Fin. | - | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/2001 | Financial Ratios | ||||
| Total Assets | 0.56 | Current Assets | - | Current Ratio | - |
| Total Liab. | 0.63 | Current Liab. | - | Debt Ratio | 112.41% |
| Total Equity | -0.07 | Working Cap. | - | Debt to Equity Ratio | - |
| Cash | 0.13 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for product development, licensing and other marketing activities, payment of debt and general and administrative support, working capital and reserves. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Goldstein & Digioia, L.L.P. |
| Bank's Law Firm | Ellenoff Grossman Schole & Cyruli LLP. |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Grant Thornton |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Hopkins Capital Group II. LLC | 60.72 | |
| Albany Medical College | 8.04 | |
| University of Medicine and Dentistry of New Jersey | 2.79 | |
| Note: represents ownership of 5% or more prior to the offering. | ||
| Warrant Information | |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||